NCT04370379View on ClinicalTrials.gov

Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

May 8, 2021

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

IBI302 (the first dose level)

q4week (3 injections) followed by PRN dosing

DRUG

IBI302 (the second dose level)

q4week (3 injections) followed by PRN dosing

DRUG

Aflibercept

2mg, q4week (3 injections) followed by q8week

Trial Locations (1)

200080

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04370379 - Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients | Biotech Hunter | Biotech Hunter